SANDOSTATIN LAR

Negara: Indonesia

Bahasa: Bahasa Indonesia

Sumber: Badan Pengawas Obat dan Makanan RI - Indonesian Food and Drug Supervisory Agency

Bahan aktif:

OCTREOTIDE ACETATE

Tersedia dari:

NOVARTIS INDONESIA - Indonesia

INN (Nama Internasional):

OCTREOTIDE ACETATE

Dosis:

22.4 MG

Bentuk farmasi:

SERBUK INJEKSI

Unit dalam paket:

DUS, 1 VIAL @ 625 MG + 1 PRE FILLED SYRINGE @ 2 ML PELARUT + 1 VI...

Diproduksi oleh:

SANDOZ GMBH - Austria

Tanggal Otorisasi:

2021-04-19

Karakteristik produk

Page 1
1
TRADE NAME(S)
SANDOSTATIN
®
LAR
®
10 mg* powder and solvent for suspension for injection.
SANDOSTATIN
®
LAR
®
20 mg powder and solvent for suspension for injection.
SANDOSTATIN
®
LAR
®
30 mg powder and solvent for suspension for injection.
2
DESCRIPTION AND COMPOSITION
PHARMACEUTICAL FORM(S)
Powder and solvent for suspension for injection.
KIT WITH VIAL ADAPTER AND SAFETY NEEDLE:
Powder: white to off-white powder.
Solvent for suspension for injection: clear, colourless to slightly
yellow or brown solution.
Sandostatin
®
LAR
®
is a long-acting depot injection form of octreotide. Powder
(microspheres for
suspension for injection) to be suspended in a vehicle immediately
prior to i.m. injection.
Sandostatin LAR suspension contain less than 1 mmol (23 mg) of sodium
per dose, i.e. essentially
‘sodium-free’.
ACTIVE SUBSTANCE(S)
The active substance is octreotide free peptide. 10 mg*, 20 mg or 30
mg nominally 4.15% of fill weight
equivalent to 4.65% of octreotide acetate.
EXCIPIENTS
VIAL
Poly (DL-lactide-co-glycolide) 78.35% of nominal fill weight; sterile
mannitol 17.0% of nominal fill
weight.
PREFILLED SYRINGE
KIT WITH VIAL ADAPTER AND SAFETY NEEDLE:
One PREFILLED SYRINGE (solvent for parenteral use), containing: sodium
carboxymethylcellulose (14 mg),
mannitol (12 mg), poloxamer 188 (4 mg); water for injection qs ad 2
mL.
3
INDICATIONS
Treatment of patients with acromegaly:
-
Who are adequately controlled on s.c. treatment with Sandostatin
-
_In whom_ surgery, radiotherapy or dopamine agonist treatment is
inappropriate or ineffective, or in the
interim period until radiotherapy becomes fully effective (see Dosage
regimen and administration)
Relief of symptoms associated with gastro-entero-pancreatic endocrine
tumors:
-
Carcinoid tumors with features of the carcinoid syndrome
-
VIPomas
-
Glucagonomas
Treatment of patients with advanced Neuroendocrine Tumors of the
midgut.
DISETUJUI OLEH BPOM : 12/04/2022
ID : EEREG10000512000212
REG10000512000213
Page 2
4
DOSAGE REGIMEN AND ADMINISTRATION
Sandostat